Lipid profiling of cancerous and benign gallbladder tissues by 1H NMR spectroscopy

NMR in Biomedicine

Volumn 24, Issue 4, 2011, Pages 335-342

  Jayalakshmi, Kamaiah ^a   Sonkar, Kanchan ^a   Behari, Anu ^b   Kapoor, Vinay K ^b   Sinha, Neeraj ^a  

^a Center for Bio Medical Magnetic Resonance Lucknow   (India)

^b SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

1H NMR; Chronic cholecystitis; Gallbladder cancer; Lipid profiling; Plasmalogen; Xanthogranulomatous cholecystitis

Indexed keywords

1H NMR; CHRONIC CHOLECYSTITIS; GALLBLADDER CANCER; PLASMALOGEN; XANTHOGRANULOMATOUS CHOLECYSTITIS;

DISEASES; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHOLIPIDS; TISSUE;

BIOLOGICAL ORGANS;

CHOLESTEROL; LIPID; PLASMALOGEN;

ADULT; AGED; ARTICLE; CANCER TISSUE; CHOLECYSTECTOMY; CHOLECYSTITIS; CHOLESTEROL BLOOD LEVEL; CHRONIC CHOLECYSTITIS; CLINICAL ARTICLE; DIAGNOSTIC IMAGING; FEMALE; GALLBLADDER; GALLBLADDER CANCER; GALLBLADDER TISSUE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIPID ANALYSIS; MALE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RISK FACTOR; SIGNAL TRANSDUCTION; XANTHOGRANULOMATOUS CHOLECYSTITIS;

CHOLECYSTITIS; CHOLESTEROL ESTERS; GALLBLADDER; GALLBLADDER NEOPLASMS; GRANULOMA; HUMANS; LIPID METABOLISM; MAGNETIC RESONANCE SPECTROSCOPY; MUCOUS MEMBRANE; PHOSPHOLIPIDS; PLASMALOGENS; PROTONS; TRIGLYCERIDES; XANTHOMATOSIS;

EID: 79959599118     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1594     Document Type: Article

References (52)

1. Diehl AK, Beral V. Cholecystectomy and changing mortality from gallbladder cancer. Lancet, 1981; 2: 187-189.
2. Kapoor VK. Advanced gallbladder cancer: Indian 'middle path'. J. Hepatobiliary Pancreat. Surg. 2007; 14: 366-373.
3. Kapoor VK, McMichael AJ. Gallbladder cancer: an 'Indian' disease. Natl. Med. J. India, 2003; 16: 209-213.
4. Nervi F, Duarte I, Gomez G, Rodriguez G, Del Pino G, Ferrerio O, Covarrubias C, Valdivieso V, Torres MI, Urzua A. Frequency of gallbladder cancer in Chile, a high-risk area. Int. J. Cancer, 1988; 41: 657-660.
5. Tazuma S, Kajiyama G. Carcinogenesis of malignant lesions of the gall bladder. The impact of chronic inflammation and gallstones. Langenbecks Arch. Surg. 2001; 386: 224-229.
6. 13C NMR analysis of human gallstones from cancer and benign gall bladder diseases. Solid State Nucl. Magn. Reson. 2009; 36: 60-65.
7. Roa I, Araya JC, Villaseca M, De Aretxabala X, Riedemann P, Endoh K, Roa J. Preneoplastic lesions and gallbladder cancer: an estimate of the period required for progression. Gastroenterology, 1996; 111: 232-236.
8. Chan PH, Fishman RA. Alterations of membrane integrity and cellular constituents by arachidonic acid in neuroblastoma and glioma cells. Brain Res. 1982; 248: 151-157.
9. Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology, 2003; 144: 2201-2207.
10. Cerussi A, Shah N, Hsiang D, Durkin A, Butler J, Tromberg BJ. In vivo absorption, scattering, and physiologic properties of 58 malignant breast tumors determined by broadband diffuse optical spectroscopy. J. Biomed. Opt. 2006; 11: 044005. 1-16.
11. Redd DCB, Feng ZC, Yue KT, Gansler TS. Raman spectroscopic characterization of human breast tissues: implications for breast cancer diagnosis. Appl. Spectrosc. 1993; 47: 787-791.
12. Plas E, Carroll VA, Jilch R, Simak R, Mihaly J, Melchior S, Thuroff JW, Binder BR, Pfluger H. Variations of components of the plasminogen activation system with the cell cycle in benign prostate tissue and prostate cancer. Cytometry, 2001; 46: 184-189.
13. Tsambaos D, Kalofoutis A, Stratigos J, Miras C, Capetanakis J. Thin-layer chromatography of phospholipid components of normal and psoriatic epidermis. Br. J. Dermatol. 2006; 97: 135-138.
14. Goto J, Nambara T. Bile Acids. In Liquid Chromatography in Biomedical Analysis, Hanai T (ed). Elsevier Science Publishers: Amsterdam, 1991; 81-108.
15. Goto J, Mano N, Goto T. Development of highly selective analytical systems for biological substances using chromatography combined with mass spectrometry - with special reference to bio-analytical studies of bile acids. Chromatography, 2004; 25: 1-8.
16. 1H NMR spectroscopy, HPLC-NMR/MS and UPLC-MS. Mol. Biosyst. 2009; 5: 180-190.
17. 1H-NMR spectroscopy. J. Gastrointest. Liver Dis. 2009; 18: 27-32.
18. 13C NMR characterization and stereochemical assignments of bile acids in aqueous media. Lipids, 2005; 40: 1031-1041.
19. Beckonert O, Keun HC, Ebbels TM, Bundy J, Holmes E, Lindon JC, Nicholson JK. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat. Protoc. 2007; 2: 2692-2703.
20. Srivastava NK, Pradhan S, Mittal B, Kumar R, Gowda GA. An improved, single step standardized method of lipid extraction from human skeletal muscle tissue. Anal Lett. 2006; 39: 297-315.
21. 31P NMR based analysis of the lipid components in the tissue, serum, and CSF of the patients with primary brain tumors: one possible diagnostic view. NMR Biomed. 2010; 23: 113-122.
22. Subramanian A, Joshi BS, Roy AD, Roy R, Gupta V, Dang RS. NMR spectroscopic identification of cholesterol esters, plasmalogen and phenolic glycolipids as fingerprint markers of human intracranial tuberculomas. NMR Biomed. 2007; 21: 272-288.
23. Kriat M, Vion-Dury J, Confort-Gouny S, Favre R, Viout P, Sciaky M, Sari H, Cozzone PJ. Analysis of plasma lipids by NMR spectroscopy: application to modifications induced by malignant tumors. J. Lipid Res. 1993; 34: 1009-1019.
24. Tzika AA, Astrakas L, Cao H, Mintzopoulos D, Andronesi OC, Mindrinos M, Zhang J, Rahme LG, Blekas KD, Likas AC, Galatsanos NP, Carroll RS, Black PM. Combination of high-resolution magic angle spinning proton magnetic resonance spectroscopy and microscale genomics to type brain tumor biopsies. Int. J. Mol. Med. 2007; 20: 199-208.
25. 31P measurements of response to treatment. NMR Biomed. 1998; 11: 314-340.
26. 31P NMR spectroscopy of blood plasma: determination and quantification of phospholipid classes in patients with renal cell carcinoma. NMR Biomed. 2002; 15: 60-68.
27. 31P magnetic resonance spectroscopy. Int. J. Colorectal Dis. 1991; 6: 121-126.
28. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res. 1999; 59: 80-84.
29. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed. 1992; 5: 303-324.
30. Katz-Brull R, Seger D, Rivenson-Segal D, Rushkin E, Degani H. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res. 2002; 62: 1966-1970.
31. 31P NMR of extracted phospholipids. J. Lipid Res. 1988; 29: 679-689.
32. Nelson DL, Cox MM. Chapter title. In Lehninger Principles of Biochemistry, Ryan M (ed). Worth Publisher: New York, 2008; 805-850.
33. Beloueche-Babari M, Peak JC, Jackson LE, Tiet MY, Leach MO, Eccles SA. Changes in choline metabolism as potential biomarkers of phospholipase C{gamma}1 inhibition in human prostate cancer cells. Mol. Cancer Ther. 2009; 8: 1305-1311.
34. Podo F. Tumour phospholipid metabolism. NMR Biomed. 1999; 12: 413-439.
35. 31P MRS of experimental tumours. NMR Biomed. 1993; 6: 345-365.
36. Glunde K, Ackerstaff E, Mori N, Jacobs MA, Bhujwalla ZM. Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol. Pharmacol. 2006; 3: 496-506.
37. Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S, Podo F. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 2005; 65: 9369-9376.
38. Larrodera P, Cornet ME, Diaz-Meco MT, Lopez-Barahona M, Diaz-Laviada I, Guddal PH, Johansen T, Moscat J. Phospholipase C-mediated hydrolysis of phosphatidylcholine is an important step in PDGF-stimulated DNA synthesis. Cell, 1990; 61: 1113-1120.
39. Cuadrado A, Carnero A, Dolfi F, Jiménez B, Lacal J. Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors. Oncogene, 1993; 8: 2959-2968.
40. 31P nuclear magnetic resonance study in vivo and in vitro. Magn. Reson. Med. 1999; 41: 897-903.
41. Ronen SM, Jackson LE, Beloueche M, Leach MO. Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br. J. Cancer, 2001; 84: 691-696.
42. Tosi MR, Fini G, Tinti A, Reggiani A, Tugnoli V. Molecular characterization of human healthy and neoplastic cerebral and renal tissues by in vitro (1)H NMR spectroscopy (review). Int. J. Mol. Med. 2002; 9: 299-310.
43. 1H-NMR detectable fatty acyl chain unsaturation in excised leiomyosarcoma correlates with grade and mitotic activity. J. Clin. Invest. 1996; 98: 244-250.
44. Tosi MR, Ricci R, Bottura G, Tugnoli V. In vivo and in vitro nuclear magnetic resonance spectroscopy investigation of an intracranial mass. Oncol. Rep. 2001; 8: 1337-1339.
45. 1H nuclear magnetic resonance spectroscopy. Anal. Biochem. 1996; 236: 41-48.
46. Rudling MJ, Angelin B, Peterson CO, Collins VP. Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement. Cancer Res. 1990; 50: 483-487.
47. Murakami M, Ushio Y, Mihara Y, Kuratsu J, Horiuchi S, Morino Y. Cholesterol uptake by human glioma cells via receptor-mediated endocytosis of low-density lipoprotein. J. Neurosurg. 1990; 73: 760-767.
48. Smith RE, Lespi P, Di Luca M, Bustos C, Marra FA, de Alaniz MJ, Marra CA. A reliable biomarker derived from plasmalogens to evaluate malignancy and metastatic capacity of human cancers. Lipids, 2008; 43: 79-89.
49. Albi E, Cataldi S, Magni MV, Sartori C. Plasmalogens in rat liver chromatin: new molecules involved in cell proliferation. J. Cell Physiol. 2004; 201: 439-446.
50. Lanza-Jacoby S, Lansey SC, Miller EE, Cleary MP. Sequential changes in the activities of lipoprotein lipase and lipogenic enzymes during tumor growth in rats. Cancer Res. 1984; 44: 5062-5067.
51. Noguchi Y, Vydelingum NA, Younes RN, Fried SK, Brennan MF. Tumor-induced alterations in tissue lipoprotein lipase activity and mRNA levels. Cancer Res. 1991; 51: 863-869.
52. 1H nuclear magnetic resonance visible polyunsaturated fatty acids in BT4C gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death. Cancer Res. 2003; 63: 3195-3201.